



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

GFH44AF Recombinant Human VEGF-165 (Animal-Free)

Description

Vascular Endothelial Growth Factor A (VEGF-A) is produced by a wide variety of cell types, including tumor and vascular cells. VEGF-A is a mediator of vascular growth, vascular permeability, and plays a role in stimulating vasodilation via nitric oxide-dependent pathways. VEGF-A has several alternatively spliced isoforms, with VEGF-165 being the most abundant. The VEGF-165 isoform is a secreted protein that acts on receptors VEGFR-1 and VEGFR-2 to modulate endothelial cell proliferation and angiogenesis.

This product is produced with no animal derived raw products. All processing and handling employs animal free equipment and animal free protocols.

Length	166 / 332 aa
Molecular Weight	19.3 / 38.6 kDa
Source	E. coli
Accession Number	P15692-4
Purity	≥95% determined by reducing and non-reducing SDS-PAGE


Specifications

Alternative Names	Vascular Endothelial Growth Factor, VEGF165, VEGF-A, VPF, glioma-derived endothelial cell mitogen
Biological Activity	Human VEGF-165 (Animal-Free) is fully biologically active when compared to standard. The activity is determined by the proliferation of HUVEC cells and it is typically less than 10 ng/ml. This corresponds to an expected specific activity of 1×10^5 units/mg.
Endotoxin Level	≤1.00 EU/μg as measured by kinetic LAL
Formulation	Lyophilized from a sterile (0.2 micron) filtered aqueous solution containing 0.1% Trifluoroacetic Acid (TFA)
AA Sequence	MAPMAEGGGQ NHHEVVKFMD VYQRSYCHPI ETLVDIFQEY PDEIEYIFKP SCVPLMRCGG CCNDEGLECV PTEESNITMQ IMRIKPHQGQ HIGEMSFLQH NKCECRPKKD RARQENPCGP CSERRKHLFV QDPQTCKCSC KNTDSRCKAR QLELNERTCR CDKPRR


Preparation and Storage

Reconstitution	Centrifuge vial before opening. When reconstituting the product, gently pipet and wash down the sides of the vial to ensure full recovery of the protein into solution. It is recommended to reconstitute the lyophilized product with sterile water at 0.1 mg/ml, which can be further diluted into other aqueous solutions.
Stability and Storage	12 months from date of receipt when stored at -20°C to -80°C as supplied. 1 month when stored at 4°C after reconstituting as directed. 3 months when stored at -20°C to -80°C after reconstituting as directed.

Data



Induced proliferation of HUVEC cells for Human VEGF-165 (Animal-Free). Cell proliferation was measured to calculate the ED50, which is as expected less than 10 ng/ml.



Non-reducing (-) and reducing (+) conditions in a 4 - 20% Tris-Glycine gel stained with Coomassie Blue. 1 μg of protein was loaded in each lane. Human VEGF-165 has a predicted Mw of 38.6 kDa.